1. Home
  2. USDE vs NNNN Comparison

USDE vs NNNN Comparison

Compare USDE & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo StablecoinX Inc. Class A Common Stock

USDE

StablecoinX Inc. Class A Common Stock

N/A

Current Price

$5.22

Market Cap

146.1M

Sector

N/A

ML Signal

N/A

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

N/A

Current Price

$3.81

Market Cap

154.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
USDE
NNNN
Founded
N/A
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.1M
154.1M
IPO Year
2026
2023

Fundamental Metrics

Financial Performance
Metric
USDE
NNNN
Price
$5.22
$3.81
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 929.2K
45.9K
Earning Date
11-16-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$446.57
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$3.09
52 Week High
$17.50
$44.73

Technical Indicators

Market Signals
Indicator
USDE
NNNN
Relative Strength Index (RSI) 31.07 43.58
Support Level $1.33 $3.21
Resistance Level $9.02 $6.95
Average True Range (ATR) 0.94 0.35
MACD -0.32 0.13
Stochastic Oscillator 0.72 42.92

Price Performance

Historical Comparison
USDE
NNNN

About USDE StablecoinX Inc. Class A Common Stock

StableCoinX Inc is a newly-formed validator and infrastructure business expected to operate infrastructure and staking services, running validators and related technical services for the Ethena protocol. The company is expected to adopt a multi-year treasury strategy to build a reserve of ENA, the Ethena protocol's native token.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: